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Abstract
Background Patients with atrial septal defects (ASD) are
often misdiagnosed as asthma patients and accordingly re-
ceive erroneous bronchodilator treatment. In order to char-
acterise their symptoms of dyspnoea to explain this clinical
observation, we investigated the prevalence of asthma-like
symptoms in patients with secundum ASD who then un-
derwent successful percutaneous closure.
Methods A total of 80 ASD patients (74 % female, mean
age 46.7 ± 16.8 years, median follow-up 3.0 [2.0–5.0]
years) retrospectively completed dyspnoea questionnaires
determining the presence and extent of cough, wheezing,
chest tightness, effort dyspnoea and bronchodilator use
on a 7-point scale (0 = none, 6 = maximum) before and
after ASD closure. The Mini Asthma Quality of Life
(Mini-AQLQ) and Asthma Control Questionnaire with
bronchodilator use (ACQ6) were administered.
Results A total of 48 (60 %) patients reported cough, 27
(34 %) wheezing, 26 (33 %) chest tightness and 62 (78 %)
effort dyspnoea. Symptom resolution or reduction was
found in 64 (80 %) patients after ASD closure. Asthma
symptom scores decreased significantly on the Mini-AQLQ
and ACQ6 (both p < 0.001). The number of patients using
bronchodilators decreased from 16 (20 %) to 8 (10 %) pa-
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tients after ASD closure (p = 0.039) with less frequent use
of bronchodilators (p = 0.015).
Conclusions A high prevalence of asthma-like symptoms
and bronchodilator use is present in ASD patients, which
exceeds the low prevalence of bronchial asthma in this study
population. Future prospective research is required to con-
firm this phenomenon. The presence of an ASD should
be considered in the differential diagnosis of patients with
asthma-like symptoms, after which significant symptom re-
lief can be achieved by ASD closure.
Keywords Heart septal defects · Atrial Dyspnoea ·
Bronchial hyperreactivity · Asthma · Device closure
Introduction
The ostium secundum atrial septal defect (ASD) is one of
the most commonly diagnosed congenital heart diseases
among adults. Patients with ASD usually present with
symptoms of dyspnoea, which may develop with increasing
age. Due to the epidemiologically more prevalent asthma
in the general population, we observed that dyspnoeic ASD
patients are often erroneously diagnosed with asthma and
receive lengthy bronchodilator treatment. Delay in the cor-
rect diagnosis and treatment of ASD leads to complications
of long-standing right ventricular volume and eventually
pressure overload such as atrial arrhythmias, paradoxical
embolism, pulmonary hypertension and right ventricular
failure [1, 2].
Percutaneous ASD closure is the treatment of choice in
haemodynamically significant left-to-right shunts with suit-
able anatomy [3]. Previous studies have already shown dys-
pnoea to decrease after percutaneous closure, and several
have indeed found objective pulmonary function improve-
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Fig. 1 Symptom severity and scores of the Mini-AQLQ and ACQ at
baseline (square) and follow-up (circle) in asthmatics (left, n = 6) and
non-asthmatics (right, n = 74) separately. Values are given in median
[25th–75th percentile]. Score 0 = none, 1 = a very little, 2 = a little, 3 =
a moderate amount, 4 = quite a lot, 5 = a great deal, 6 = a very great
deal. *p < 0.001
Fig. 2 The frequency of bronchodilator use as assessed by the ACQ6
in patients with current bronchodilator use (n = 16) at baseline (square)
and follow-up (circle) separated as asthmatics (left) versus non-asth-
matics (right). Values are given in median [25th–75th percentile]. Score
0 = none, 1 = 1–2 puffs most days, 2 = 3–4 puffs most days, 3 =
5–8 puffs most days, 4 = 9–12 puffs most days, 5 = 13–16 puffs most
days, 6 = more than 16 puffs most days
ment by cardiopulmonary exercise testing [4–7]. However,
to date the characteristics of dyspnoea reported by these
ASD patients have not been investigated.
The purpose of this study was to examine the prevalence
of asthma-like symptoms in patients with ASD, and investi-
gate whether percutaneous closure of the left-to-right shunt
affects asthma-like symptoms both in diagnosed asthma pa-
tients and in non-asthmatics.
Methods
Patient population
Between 2005 and 2013 a total of 105 consecutive adult
patients underwent percutaneous closure of an ASD in our
centre using the Amplatzer Septal Occluder device (AGA
Medical, Minneapolis, Minnesota, USA). Of the 89 patients
with successful percutaneous closure of their ASD (16 con-
verted to surgery), 80 patients were available for follow-up
and were therefore included in this study. Follow-up was
fully obtained (n = 80). This study was conducted in accor-
dance with all human research regulatory guidelines and
the need to obtain informed consent was waived by the
institutional ethics committee.
Procedure
Percutaneous ASD closure was performed under general
anaesthesia for transoesophageal echocardiography guid-
ance to ensure optimal device placement. Heparin and
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aspirin were routinely administered at the start of the proce-
dure. Successful ASD closure was defined as correct device
position without post-procedural complications.
Follow-up evaluation
Patients were discharged one day post-procedurally
after confirming a complete ASD closure on transtho-
racic echocardiography (TTE). Aspirin (100 mg daily) and
clopidogrel (600 mg loading dose and 75 mg daily) were
prescribed for six months along with standard endocarditis
prophylaxis. Patients were followed clinically and TTE
was performed at least one day and six months after device
implantation.
Definition of outcomes
Primary outcomes were the prevalence of asthma-like
symptoms, defined as wheeze, chest tightness, cough, ef-
fort dyspnoea and bronchodilator use, before and after
successful percutaneous ASD closure. Secondary outcome
measures were the Mini Asthma Quality of Life Ques-
tionnaire symptom and environmental score (Mini-AQLQ,
minimum clinically significant difference =0.5) and asthma
control level (Asthma Control Questionnaire with bron-
chodilator use, ACQ6) [8–10]. The extent of asthma-like
symptoms was quantified using the same score range as
the above-mentioned validated questionnaires (range 0–6,
lower score indicating less symptoms) as conducted by
telephone contact.
The primary and secondary outcomes are defined in the
overall group, as well as in the subgroups of asthmatics and
non-asthmatics. Asthmatics are defined as patients with
a physician’s diagnosis of bronchial asthma by presence
of variable expiratory airflow obstruction. Conveniently,
symptoms of wheezing, chest tightness, cough and effort
dyspnoea are referred to as asthma-like symptoms, even if
reported by patients with bronchial asthma.
Statistical analysis
The Mini-AQLQ score was inverted for data analyses to
be consistent with a lower score indicating less severity.
Dichotomous variables were analysed using the McNemar
test and are expressed as frequency (percentage). The con-
tinuous, non-parametric variables were analysed using the
Wilcoxon signed-rank test (baseline vs. follow-up) and the
Mann-Whitney-U test (asthmatics vs. non-asthmatics) and
are expressed as median (25th–75th percentile). A p value
<0.05 was considered statistically significant. All statis-
tical analyses were made using IBM SPSS Statistics for
Windows, Version 21 (IBM Corp., Armonk, NY, USA).
Results
ASD closure
Baseline characteristics of the 80 patients with successful
percutaneous closure are shown in Table 1. TTE follow-
up at six to nine months post-procedurally was available in
all patients and showed a trivial residual shunt in six pa-
tients (8 %). No device- or procedure-related complications
occurred during clinical follow-up.
Asthma-like symptoms
Of all 80 patients with unrepaired ASD, 48 reported cough
(60 %), 27 wheezing (34 %), 26 chest tightness (33 %) and
62 effort dyspnoea (78 %). After successful percutaneous
closure, 64 (80 %) reported either complete resolution or
Table 1 Baseline characteristics of unrepaired ASD patients
n = 80
Demographics
Age (years) 46 ±16.8
Sex (male) 21 (26 %)
Body mass index (kg/m²) 25.6 ±4.6
Former smoker 14 (18 %)
Current smoker 17 (21 %)
Clinical history
COPDa 2 (3 %)
Bronchial asthmaa 6 (8 %)
Atopic constitutionb 14 (18 %)
Pulmonary hypertensionc 5 (6 %)
Myocardial infarction 0 (0 %)
Acute heart failure 7 (9 %)
– Right ventricular 5 (6 %)
Arrhythmia 19 (24 %)
ASD-related characteristicsd
SPAP (mm Hg) 35 [30–41]
RVEDV (ml) 239 ±117
Qp:Qs ratio 1.8 [1.4–2.0]
Defect size (mm) 17.7 ±7.5
Device size (mm) 21.8 ±7.4
Closure indication
– Right ventricular overload 71 (89 %)
– Paradoxical embolism 9 (11 %)
Values are in numbers (%), mean ± SD or median [25th–75th per-
centile]. COPD chronic obstructive pulmonary disease; SPAP systolic
pulmonary artery pressure, normally 36 mm Hg; RVEDV right ven-
tricular end-diastolic volume, normal range 100–160 ml; Qp Qs ratio
pulmonary to systemic shunt fraction
aphysician’s diagnosis by pulmonary function testing; batopic dermati-
tis, allergic rhinitis and/or bronchial asthma; cdefined as right ventric-
ular systolic pressure ≥50 mm Hg on echocardiography; dmeasured on
echocardiography
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symptom reduction (p < 0.001) at a median follow-up of
3.0 (2.0–5.0) years.
Table 2 and 3 show the quantified effect of ASD closure
on asthma-like symptoms and in the Mini-AQLQ (symptom
and environment domain) and ACQ6 (bronchodilator use
separately and within the overall ACQ6 score). Symptom
severity significantly decreased from baseline to follow-
up in all questionnaire scores. This effect was found in
both asthmatics and non-asthmatics, although in the latter
a larger change was observed (Fig. 1).
Bronchodilator use
Of all 80 patients, 16 patients (20 %) reported current bron-
chodilator use, which decreased to eight patients (10 %)
after closure (p = 0.039). The prevalence and frequency of
use is shown in Fig. 2. In contrast with the significantly
reduced frequency in non-asthmatics, asthmatic ASD pa-
tients continued to use bronchodilators and in the same
frequency as before closure. One asthmatic patient had no
current bronchodilator use at baseline but started using them
in the period after closure, making up a total of eight pa-
tients (10 %) with current bronchodilator use at follow-up.
Table 2 Prevalence of asthma-like symptoms in ASD patients with and without asthma and the impact of transcatheter closure
All patients
Values are in numbers (%)
Non-asthmatics
Values are in numbers (%)
Asthmatics
Values are in numbers (%)
n = 80 n = 74 n=6
Baseline symptom prevalence
Cough 48 (60) 43 (58) 5 (83)
Wheezing 27 (34) 21 (28) 6 (100)
Chest tightness 26 (33) 23 (31) 3 (50)
Effort dyspnoea 62 (78) 57 (77) 5 (83)
None 10 (13) 10 (14) 0 (0)
Symptom resolution
Cough 8/48 (17)* 6/43 (14) 2/5 (40)
Wheezing 14/27 (52)** 12/21 (57) 2/6 (33)
Chest tightness 13/26 (50)*** 11/23 (48) 2/3 (67)
Effort dyspnoea 14/62 (23)*** 13/57 (23) 1/5 (20)
Symptom reduction
Cough 19/48 (40)*** 17/43 (40) 2/5 (40)
Wheezing 5/27 (19)*** 3/21 (14) 2/6 (33)
Chest tightness 7/26 (27)*** 7/23 (30) 0/3 (0)
Effort dyspnoea 38/62 (61)*** 34/57 (60) 4/5 (80)
Overall symptom score change
Resolution or reduction 64/80 (80)*** 58/74 (78) 6/6 (100)
Any symptom 30/80 (38) 28/74 (38) 2/6 (33)
≥2 symptoms 34/80 (43) 30/74 (41) 4/6 (67)
Equal 16/80 (20)a 15/74 (20) 1/6 (17)
Worsening 1/80 (1) 1/74 (1) 0/6 (0)
Symptom reduction and score change is defined as a ≥ 1 grade change on a 7-point scale; percentages may not sum to 100 % due to rounding; ASD
atrial septal defect; *p < 0.05. **p = 0.001; ***p < 0.001 in relation with baseline incidence of symptoms
aincludes all ten asymptomatic patients at baseline
Discussion
The results of our observational study show a high preva-
lence of asthma-like symptoms in yet unrepaired ASD pa-
tients: 70 of 80 patients (88 %) reported cough, wheezing,
chest tightness and/or effort dyspnoea. This cannot be ac-
counted for by the low prevalence of either the number of
diagnosed asthma patients in this study population (8 %) or
the prevalence of bronchial hyperreactivity in the general
Dutch population (maximum 25 % including asymptomatic
patients) [11]. Percutaneous ASD closure results in symp-
tom resolution or significant reduction (≥1 grade on a 7-
point scale) in the majority of patients (80 %, p < 0.001),
both in non-asthmatics and asthmatics alike.
Bronchial asthma is characterised by variable airflow
limitation and by airway hyperreactivity, which represents
an exaggerated contractile response of the airway smooth
muscle to various stimuli [12]. Atopy is the strongest identi-
fiable risk factor for the development of asthma. Pulmonary
congestion by congenital heart disease has been suggested
to increase the risk of atopic asthma in genetically pre-
disposed children, and most reports of coexisting asthma
in congenital heart disease attributed this to the presence
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Table 3 Quantification of symptom improvement and bronchodilator use at baseline and follow-up
n Baseline Follow-up p value
Symptom score
Cough 48 2.00 [1.00–4.00] 1.00 [1.00–2.00] p < 0.001
Wheezing 27 2.00 [1.00–2.00] 0.00 [0.00–1.00] p < 0.001
Chest tightness 26 2.00 [2.00–3.00] 0.50 [0.00–2.00] p < 0.001
Effort dyspnoea 62 5.00 [3.00–6.00] 2.00 [1.00–3.00] p < 0.001
Symptom mean score 70 1.50 [0.81–2.50] 0.50 [0.25–1.19] p < 0.001
Mini-AQLQ
Symptom domain score 80 0.75 [0.25–1.69] 0.25 [0.00–0.75] p < 0.001
Environment domain score 80 0.00 [0.00–1.00] 0.00 [0.00–0.67] p = 0.006
ACQ6
ACQ6 mean score 80 0.67 [0.00–1.67] 0.00 [0.00–0.50] p < 0.001
Bronchodilator use 80 16 (20 %) 8 (10 %) p = 0.039
Score bronchodilator use 16 3.00 [1.50–3.00] 0.00 [0.00–2.50] p = 0.015
Values are in median [25th–75th percentile] or in numbers (percentages); all given scores are presented as the questionnaire mean score, range 0 =
minimum and 6 = maximum
Mini-AQLQ Mini Asthma Quality of Life Questionnaire; ACQ6 Asthma Control Questionnaire with bronchodilator use
of pulmonary hypertension [13–15]. In our patient popula-
tion, however, only a small percentage of atopic constitution
(18 %) and a very low Mini-AQLQ environment domain
score (median 0.00 [0.00–1.00]) was present. Similarly,
pulmonary hypertension was diagnosed using echocardio-
graphy in only five patients (6 %), albeit in the absence
of dynamic stress echocardiography to potentially detect
latent pulmonary hypertension [16, 17]. Furthermore, in
this study ASD patients with diagnosed bronchial asthma
showed symptom reduction similar to the non-asthmatics.
The reported asthma-like symptoms are therefore unlikely
fully the result of the bronchial asthma itself, but rather due
to a related mechanism common in all ASD patients.
Alternatively, the left-to-right shunt in ASD patients
might contribute to any of the inflammatory, physiological,
and structural factors in the pathogenesis of asthma or
in the initiation of bronchial hyperreactivity. Several ex-
perimental studies have suggested an association between
bronchial hyperreactivity and impaired left ventricular
function, chronic elevation in left atrial pressure, and pre-
capillary pulmonary hypertension due to aorto-caval shunts
[18–20]. In clinical studies, bronchial hyperreactivity has
been reported in patients with lung congestion secondary to
mitral valve disease, ischaemic heart disease, and chronic
heart failure [21–24]. The proposed mechanisms are inter-
stitial and/or airway wall oedema, bronchial wall muscle
hypertrophy [25], or reflex bronchoconstriction, all due to
pulmonary or bronchial vascular engorgement [21, 24–26].
In normal subjects, increased cardiac output by rapid saline
infusion actuated bronchial hyperreactivity, supposedly
by mechanical impingement of the airway lumen by in-
creased mucosal thickness [27]. Also, when prohibiting
deep breaths in normal subjects, loss of smooth muscle
relaxation led to acute airway narrowing and bronchial
hyperreactivity, implying that asthma-like symptoms can
be imitated in case of impaired deep inspiration [28, 29].
In support of these findings, left-to-right shunting in ASD
patients might similarly augment bronchial hyperreactivity,
resulting in asthma-like symptomatology.
Whichever pathophysiological mechanism is responsi-
ble, asthma-like symptoms in ASD patients decrease sig-
nificantly after closure of the defect. The possibility exists
of wrongly diagnosing asthma in such patients while they
should be recognised as potential ASD patients; however,
as of yet we cannot differentiate between bronchial asthma
and ASD patients with asthma-like symptoms. Currently
the only way to obviate asthma misdiagnosis is to optimise
awareness that ASD is included in the differential diagno-
sis of bronchial asthma, especially when bronchodilation
appears insufficient. More insight into the pathophysiol-
ogy of these asthma-like symptoms is required to provide
an attainable tool for distinguishing ASD patients from the
large pool of asthmatics. Also, further studies are needed
to objectify these asthma-like symptoms, e. g. by bron-
choprovocation testing.
Several limitations must be noted. This study had a retro-
spective design, therefore the questionnaire results relied on
patients’ recollection of symptoms. Although paired testing
was performed to provide for per-patient changes, as of now
the Mini-AQLQ and ACQ6 questionnaires are validated in
asthmatics only. Questions on dyspnoea and wheezing are
acceptably sensitive and specific for detecting bronchial hy-
perreactivity in the general population, but patient-reported
outcomes remain subjective. Statistical analysis of group
differences between non-asthmatics and asthmatics could
not be performed due to the small number of asthmatics in
this patient cohort; therefore, only frequency comparisons
were made.
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Conclusions
A high prevalence of patient-reported cough, wheezing,
chest tightness and effort dyspnoea is present in patients
with unrepaired ASD. Percutaneous ASD closure leads to
significant symptom resolution or reduction in the majority
of these patients (80 %, p < 0.001). The prevalence and
pathophysiology of asthma-like symptoms in this patient
population remains to be further investigated in prospective
studies.
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